BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Avagimyan A, Mkrtchyan L, Abrahomovich O, Sheibani M, Guevorkyan A, Sarrafzadegan N, Kozhukhov S, Agati L, Astengiano R, Zaritska V, Jndoyan Z. AC-Mode of Chemotherapy as a Trigger of Cardiac Syndrome X: A Case Study. Curr Probl Cardiol 2021;:100994. [PMID: 34571104 DOI: 10.1016/j.cpcardiol.2021.100994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Avagimyan A, Gvianishvili T, Gogiashvili L, Kakturskiy L, Sarrafzadegan N, Aznauryan A. Chemotherapy, hypothyroidism and oral dysbiosis as a novel risk factor of cardiovascular pathology development. Curr Probl Cardiol 2023;48:101051. [PMID: 34800544 DOI: 10.1016/j.cpcardiol.2021.101051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cyclophosphamide/doxorubicin. Reactions Weekly 2022;1926:190-190. [DOI: 10.1007/s40278-022-24468-9] [Reference Citation Analysis]
3 Avagimyan AA, Kakturskiy LV. Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. SJCEM 2022;37:105-111. [DOI: 10.29001/2073-8552-2022-37-2-105-111] [Reference Citation Analysis]
4 Avagimyan A. THE PATHOPHYSIOLOGICAL BASIS OF DIABETIC CARDIOMYOPATHY DEVELOPMENT. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. Cardiovasc Toxicol. [DOI: 10.1007/s12012-022-09721-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]